ORIC-944 free base · Synonyms: Rinzimetostat

ORIC-944 is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2).

For research use only. Not for human or veterinary use.

Target Histone Methyltransferase

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

ORIC-944 structure

CAS No.: 2369769-29-7

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
100 mg	USD 550.00	BP-00084-100mg	In stock	Get quote
250 mg	USD 850.00	BP-00084-250mg	In stock	Get quote
500 mg	USD 1,350.00	BP-00084-500mg	In stock	Get quote
1 g	USD 1,900.00	BP-00084-1g	In stock	Get quote
5 g	Inquire	BP-00084-5g	In stock	Inquire
10 g	Inquire	BP-00084-10g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

ORIC-944 is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). ORIC-944 is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer.

Biological activity

In Vivo Rinzimetostat (ORIC-944) (30, 100, 200 mg/kg; op; everyday for 50 days) induces significantly tumor regressions at all dose levels tested. Rinzimetostat (ORIC-944) (30 mg/kg; op; everyday for 30 days) demonstrates strong single agent activity to enzalutamide in prostate cancer xenograft model.

Specifications

MW (average): 456.5147
Formula: C₂₆H₂₅FN₆O
CAS No.: 2369769-29-7
Physical state: Solid
Color: white to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder 4℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

In vitro: DMSO : 100 mg/mL

Documents

References

[1]. Daemen A, et al. ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models[J]. Cancer Research, 2024, 84(6_Supplement): 6586-6586.

[2]. ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

Same target

Search Histone Methyltransferase

Same research area

Search Cancer